0001415889-18-000013.txt : 20180104 0001415889-18-000013.hdr.sgml : 20180104 20180104182334 ACCESSION NUMBER: 0001415889-18-000013 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180102 FILED AS OF DATE: 20180104 DATE AS OF CHANGE: 20180104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brege Laura CENTRAL INDEX KEY: 0001365619 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 18511502 MAIL ADDRESS: STREET 1: C/O ONYX PHARMACEUTICALS, INC. STREET 2: 2100 POWELL STREET CITY: EMERYVILLE STATE: CA ZIP: 94608 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3611 VALLEY CENTRE DRIVE STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 3611 VALLEY CENTRE DRIVE STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 form4-01042018_030120.xml X0306 4 2018-01-02 0001070494 ACADIA PHARMACEUTICALS INC ACAD 0001365619 Brege Laura 3611 VALLEY CENTRE DRIVE, SUITE 300 SAN DIEGO CA 92130 true false false false Common Stock 2018-01-02 4 M 0 15000 8.06 A 15000 D Common Stock 2018-01-02 4 M 0 10000 8.49 A 25000 D Common Stock 2018-01-02 4 S 0 25000 30.0617 D 0 D Stock option (right to buy) 8.06 2018-01-02 4 M 0 15000 0 D 2018-04-30 Common Stock 15000 0 D Stock option (right to buy) 8.49 2018-01-02 4 M 0 10000 0 D 2018-06-12 Common Stock 10000 0 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in October 2017. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.13 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. 25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of May 1, 2008. 25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of June 13, 2008. /s/ Elizabeth Carter, Attorney-in-Fact 2018-01-04